Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amoxicillin + azithromycin + omeprazole
- Development stage
- Phase 4
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A triple therapy combination used for the eradication of Helicobacter pylori (H. pylori) infection, which causes gastric and duodenal ulcers. This regimen combines omeprazole (a proton pump inhibitor that reduces stomach acid production) with two antibiotics: amoxicillin (a penicillin-class antibiotic) and azithromycin (a macrolide antibiotic). Clinical studies have shown this combination to be highly effective in eradicating H. pylori, with eradication rates of approximately 91.6% when administered as a two-week course.
02
Targets
Bacterial 50S ribosomal subunitPBP (Penicillin-binding protein family)ATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on amoxicillin + azithromycin + omeprazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amoxicillin + azithromycin + omeprazole.